All sponsors

Denali Therapeutics Inc. $DNLI

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO83%

Delay Index: of 6 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +24.0 months). See all sponsors →

Open Denali Therapeutics Inc. on the live radar map → 📅 $DNLI readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
DNL593
NCT05262023
P1/2Active, not recruitingFrontotemporal Dementia852026-12 (+13 mo)
BIIB122 225 mg
NCT06602193
P2Active, not recruitingParkinson Disease502027-03 (+10 mo)
tividenofusp alfa
NCT06075537
P2/3Enrolling by invitationMucopolysaccharidosis II992027-06
COMPASS
NCT05371613
P2/3Active, not recruitingMucopolysaccharidosis II652027-12 (+24 mo)
DNL952
NCT07354724
P1/2RecruitingLate-onset Pompe Disease322028-08
tividenofusp alfa
NCT04251026
P1/2Active, not recruitingMucopolysaccharidosis II472031-02 (+97 mo)
DNL126
NCT06181136
P1/2RecruitingMucopolysaccharidosis Type IIIA302032-07 (+47 mo)